Nuvectis Pharma price target raised to $15 from $11 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Nuvectis Pharma (NVCT) to $15 from $11 and keeps a Buy rating on the shares. The firm says a series of poster presentations provides “robust scientific rationale” for NXP900’s ongoing clinical exploration.